Department of Breast Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
The University of Iowa Holden Comprehensive Cancer Center, Iowa City, IA.
Am Soc Clin Oncol Educ Book. 2023 Jun;43:e390464. doi: 10.1200/EDBK_390464.
Triple-negative breast cancer (TNBC) is a very heterogeneous and aggressive breast cancer subtype with a high risk of mortality, even if diagnosed early. The mainstay of early-stage breast cancer includes systemic chemotherapy and surgery, with or without radiation therapy. More recently, immunotherapy is approved to treat TNBC, but managing immune-rated adverse events while balancing efficacy is a challenge. The purpose of this review is to highlight the current treatment recommendations for early-stage TNBC and the management of immunotherapy toxicities.
三阴性乳腺癌（TNBC）是一种非常异质性和侵袭性的乳腺癌亚型，即使早期诊断，死亡率也很高。早期乳腺癌的主要治疗方法包括全身化疗和手术，可辅以或不辅以放疗。最近，免疫疗法被批准用于治疗 TNBC，但在平衡疗效的同时管理免疫相关不良事件是一个挑战。本文旨在强调早期 TNBC 的当前治疗建议和免疫治疗毒性的管理。
